

Listado de Publicaciones

2018

- Women have enhanced bone loss associated with phosphaturia and CD4 cell restoration during initial antiretroviral therapy.
Enlace: <https://www.ncbi.nlm.nih.gov/pubmed/30134291>
- Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
Enlace: <https://academic.oup.com/ofid/article/5/6/ofy103/5032747>
- High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298.
Enlace: <https://www.ncbi.nlm.nih.gov/pubmed/29528986>
- ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.
Enlace: <https://academic.oup.com/cid/article/66/11/1689/4743559>
- Desde Puerto Rico podrían desarrollar nanopartículas ante nueva era clínica contra el VIH.
Enlace: <https://medicinaysaludpublica.com/desde-puerto-rico-podrian-desarrollar-nanoparticulas-ante-nueva-era-clinica-contra-el-vih/>

2017

- Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427981/>
- Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women A Phase 2 Randomized Trial.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667908/>
- Dr. Jorge Santana: A la caza de los virus que afectan a los puertorriqueños.
Enlace: <https://medicinaysaludpublica.com/dr-jorge-santana-dedica-su-carrera-a-la-investigacion-contra-el-sida/>

2016

- Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790146/>

- Se prolonga la vida de los pacientes de SIDA en Puerto Rico
Enlace: <https://medicinaysaludpublica.com/se-prologa-la-vida-de-los-pacientes-de-sida-en-puerto-rico/>

2015

- HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681296/>
- Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660025/>
- Less Bone Loss With Maraviroc-Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560904/>
- Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1–Infected Adults Receiving Long-term Antiretroviral Therapy.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721905/>
- Reductions in Plasma Cystatin C after Initiation of Antiretroviral Therapy are Associated with Reductions in Inflammation: ACTG A5224s.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445470/pdf/nihms657473.pdf>

2014

- Metabolic syndrome in relation to cardiorespiratory fitness, active and sedentary behavior in HIV+ Hispanics with and without lipodystrophy.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329015/pdf/nihms-657179.pdf>
- La resistencia bacteriana: enemigo de la salud pública. Revista puertorriqueña de Medicina y Salud Pública.
Enlace: <https://medicinaysaludpublica.com/la-resistencia-bacteriana-enemigo-de-la-salud-publica-2/>
- Puerto Rico frente al SIDA. Revista puertorriqueña de Medicina y Salud Pública.
Enlace: <https://medicinaysaludpublica.com/puerto-rico-frente-al-sida-entrevista-al-dr-jorge-santana-director-de-actu-e-investigador-principal/>

2013

- Nuevos avances en el tratamiento del paciente co-infectado con Hepatitis C y VIH.
- Perspectivas e implicaciones clínicas para la estrategia de identificación y tratamiento temprano.

- Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549598/>

2011

- Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121543/>
- Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173503/>
- Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430716/>

2010

- Bone disease in HIV infection: a practical review and recommendations for HIV care providers.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105903/>
- Detection of KPC in *Acinetobacter* spp. in Puerto Rico. Antimicrob Agents Chemother.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825984/pdf/0899-09.pdf>
- Prevalence of cardiometabolic risk factors in Hispanics living with HIV.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071519/>
- Uridine supplementation in the treatment of HIV lipodystrophy: Results of ACTG 5229.
<http://doi.org/10.1097/QAD.0b013e32833ea9bc>
- ACTG 5197: A Placebo Controlled Trial of Immunization of HIV-1 Infected Persons with a Replication Deficient Ad5 Vaccine Expressing the HIV-1 Core Protein.
<http://doi.org/10.1086/655468>
- Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naïve patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.
<http://doi.org/10.1086/651118>
- Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018341/>

2009

- Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naïve HIV-1-infected patients: a randomized trial.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771688/>
- Fatal granulomatous meningoencephalitis associated to mycobacterium mucogenicum-like microorganism: a case report.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909603/>
- Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Enlace: <https://www.nejm.org/doi/full/10.1056/NEJMoa0906768>
- Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Enlace: <https://www.ncbi.nlm.nih.gov/pubmed/19710593>
- Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.
Enlace: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2706549/>

2007

- Plasma HIV-1 RNA dynamics in antiretroviral-naïve subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Enlace: <https://academic.oup.com/jid/article/195/8/1169/817058>

2006

- A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
Enlace: <https://academic.oup.com/jid/article-lookup/doi/10.1086/509508>
- Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (ACTG A5118).
Enlace: <https://www.ncbi.nlm.nih.gov/pubmed/16964830>

2003

- A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.
Enlace: <https://miami.pure.elsevier.com/en/publications/a-randomized-trial-of-nelfinavir-and-abacavir-in-combination-with>